Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Non-Current Assets: 2021-2025

Historic Non-Current Assets for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $314.4 million.

  • Krystal Biotech's Non-Current Assets rose 16.83% to $314.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $314.4 million, marking a year-over-year increase of 16.83%. This contributed to the annual value of $313.8 million for FY2024, which is 36.17% up from last year.
  • Per Krystal Biotech's latest filing, its Non-Current Assets stood at $314.4 million for Q3 2025, which was up 5.86% from $297.0 million recorded in Q2 2025.
  • Krystal Biotech's Non-Current Assets' 5-year high stood at $314.4 million during Q3 2025, with a 5-year trough of $37.2 million in Q1 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $251.0 million (2024), whereas its average is $254.8 million.
  • Examining YoY changes over the last 5 years, Krystal Biotech's Non-Current Assets showed a top increase of 380.95% in 2022 and a maximum decrease of 5.08% in 2022.
  • Over the past 5 years, Krystal Biotech's Non-Current Assets (Quarterly) stood at $184.0 million in 2021, then decreased by 5.08% to $174.7 million in 2022, then spiked by 31.93% to $230.4 million in 2023, then skyrocketed by 36.17% to $313.8 million in 2024, then rose by 16.83% to $314.4 million in 2025.
  • Its last three reported values are $314.4 million in Q3 2025, $297.0 million for Q2 2025, and $307.6 million during Q1 2025.